These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34105823)

  • 41. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
    Sarkozy C; Ribrag V
    Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel therapeutic targets in mantle cell lymphoma.
    Martin P; Leonard JP
    Expert Opin Ther Targets; 2007 Jul; 11(7):929-40. PubMed ID: 17614761
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lenalidomide for the treatment of mantle cell lymphoma.
    Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
    Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current trials for frontline therapy of mantle cell lymphoma.
    Steiner RE; Romaguera J; Wang M
    J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bortezomib in the treatment of mantle cell lymphoma.
    Robak T
    Future Oncol; 2015; 11(20):2807-18. PubMed ID: 26347482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment for mantle cell lymphoma].
    Izutsu K
    Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Murine models in mantle cell lymphoma.
    Zullo K; Amengual JE; O'Connor OA; Scotto L
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):153-63. PubMed ID: 22687451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mantle Cell Lymphoma.
    Cheah CY; Seymour JF; Wang ML
    J Clin Oncol; 2016 Apr; 34(11):1256-69. PubMed ID: 26755518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Qualls D; Kumar A; Epstein-Peterson ZD
    Leuk Lymphoma; 2022 Nov; 63(11):2515-2527. PubMed ID: 35704674
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical management of mantle cell lymphoma in the elderly.
    Smolewski P; Rydygier D; Robak T
    Expert Opin Pharmacother; 2019 Oct; 20(15):1893-1905. PubMed ID: 31373238
    [No Abstract]   [Full Text] [Related]  

  • 54. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies.
    Burger JA; Ford RJ
    Semin Cancer Biol; 2011 Nov; 21(5):308-12. PubMed ID: 21945516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The complex landscape of genetic alterations in mantle cell lymphoma.
    Royo C; Salaverria I; Hartmann EM; Rosenwald A; Campo E; Beà S
    Semin Cancer Biol; 2011 Nov; 21(5):322-34. PubMed ID: 21945515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
    Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
    J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review.
    Njue A; Colosia A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):1-12.e7. PubMed ID: 25052050
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.